In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone
Open Access
- 1 October 2003
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (10) , 3260-3269
- https://doi.org/10.1128/aac.47.10.3260-3269.2003
Abstract
ABT-492 demonstrated potent antibacterial activity against most quinolone-susceptible pathogens. The rank order of potency was ABT-492 > trovafloxacin > levofloxacin > ciprofloxacin against quinolone-susceptible staphylococci, streptococci, and enterococci. ABT-492 had activity comparable to those of trovafloxacin, levofloxacin, and ciprofloxacin against seven species of quinolone-susceptible members of the family Enterobacteriaceae , although it was less active than the comparators against Citrobacter freundii and Serratia marcescens. The activity of ABT-492 was greater than those of the comparators against fastidious gram-negative species, including Haemophilus influenzae , Moraxella catarrhalis , Neisseria gonorrhoeae , and Legionella spp. and against Pseudomonas aeruginosa and Helicobacter pylori . ABT-492 was as active as trovafloxacin against Chlamydia trachomatis , indicating good intracellular penetration and antibacterial activity. In particular, ABT-492 was more active than trovafloxacin and levofloxacin against multidrug-resistant Streptococcus pneumoniae , including strains resistant to penicillin and macrolides, and H. influenzae , including β-lactam-resistant strains. It retained greater in vitro activity than the comparators against S. pneumoniae and H. influenzae strains resistant to other quinolones due to amino acid alterations in the quinolone resistance-determining regions of the target topoisomerases. ABT-492 was a potent inhibitor of bacterial topoisomerases, and unlike the comparators, DNA gyrase and topoisomerase IV from either Staphylococcus aureus or Escherichia coli were almost equally sensitive to ABT-492. The profile of ABT-492 suggested that it may be a useful agent for the treatment of community-acquired respiratory tract infections, as well as infections of the urinary tract, bloodstream, and skin and skin structure and nosocomial lung infections.Keywords
This publication has 33 references indexed in Scilit:
- Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995Antimicrobial Agents and Chemotherapy, 2002
- Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000Journal of Antimicrobial Chemotherapy, 2001
- Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in the United States during 1999–2000, Including a Comparison of Resistance Rates since 1994–1995Antimicrobial Agents and Chemotherapy, 2001
- Worldwide Prevalence of Antimicrobial Resistance inStreptococcus pneumoniae, Haemophilus influenzae,andMoraxella catarrhalisin the SENTRY Antimicrobial Surveillance Program, 1997–1999Clinical Infectious Diseases, 2001
- Immunologic Diagnosis of TuberculosisClinical Infectious Diseases, 2000
- New Uses for New and Old Quinolones and the Challenge of ResistanceClinical Infectious Diseases, 2000
- Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against EuropeanStaphylococcus aureusisolatesFEMS Immunology & Medical Microbiology, 1999
- Prevalence of Macrolide Resistance Mechanisms in Streptococcus pneumoniae Isolates from a Multicenter Antibiotic Resistance Surveillance Study Conducted in the United States in 1994-1995Clinical Infectious Diseases, 1999
- Identification of a 23S rRNA Gene Mutation in Clarithromycin‐Resistant Helicobacter pyloriHelicobacter, 1996
- Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolonesMolecular Microbiology, 1994